Context Clinical data supporting the use of targeted agents for the treatment of metastatic
renal cell carcinoma (RCC) are based predominantly on patients with clear cell histology …

CONTEXT: Several outstanding integrated staging systems (ISSs) have been devised for
patients with renal cell carcinoma (RCC). OBJECTIVE: To review the available literature on …

Background: Prognostic factors for progression-free survival (PFS), overall survival (OS),
and long-term OS (⩾ 30 months) were investigated in sunitinib-treated patients with …

The prognosis of patients affected by metastatic renal cell carcinoma (mRCC) has improved
markedly with targeted therapies. Unfortunately, 20–25% of the patients are refractory to …

BACKGROUND: The current study was conducted to evaluate the efficacy and safety of
everolimus in the treatment of patients with nonfunctioning neuroendocrine tumors (NETs) or …

Purpose The aim of this study was to investigate the pharmacogenetic determinants of
sunitinib-related toxicity and ethnic difference in metastatic renal cell carcinoma (mRCC) …

The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being
predominantly cytokine-based treatment to the use of targeted agents, which include …

Angiogenesis is an integral process in carcinogenesis, and molecular inhibitors of
angiogenic factors are currently being tested as treatments for cancer. Sunitinib is an oral …

Molecular‐targeted drugs specifically interfere with molecules that are frequently
overexpressed or mutated in cancer cells. As such, these drugs are generally considered to …

Inter-ethnic differences in systemic exposure, efficacy and safety have been reported for
some small molecule tyrosine kinase inhibitors (smTKIs). This variability in response related …